Navigation Links
BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
Date:8/15/2013

Fayetteville, Arkansas (PRWEB) August 15, 2013

BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,450,273, entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone," to The Board of Trustees of the University of Arkansas (U.S.), the Oschner Clinic Foundation (U.S.) and the National University Corporation Kagawa University (Japan). BiologicsMD™ is the exclusive licensee of the patent. The patent claims various forms of composition of matter for the proteins derived by the fusion between collagen-binding polypeptides bound to parathyroid hormone receptor agonists.

BiologicsMD is developing PTH-CBD™ as a novel and unique treatment for osteoporosis and other bone-related disorders. The technology originated in the laboratories of Joshua Sakon, Ph.D. (University Of Arkansas), Robert Gensure, M.D., Ph.D. (previously with the Oschner Clinic and currently with Montefiore Medical Center, NYC) and Osamu Matsushita, Ph.D. (previously with Kagawa University and currently with Okayama University).

"This is the first U.S. patent to issue from a patent family related to PTH-CBD and its use in treating diseases of the bone and other collagen-related disorders," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has pending methods patent applications in the U.S., along with patents being pursued in major worldwide markets. Because of PTH-CBD’s unique profile of selective targeting and other pharmacologic properties, we foresee a highly differentiated new product to help treat human disease.”

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11030677.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Micropharma Limited announces new agreement to commercialize novel natural health products
2. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
3. WuXi PharmaTech Announces Second-Quarter 2013 Results
4. Charm Sciences, Inc. Announces Charm® FAST PHAGE Method Accepted by EPA for Detection of Coliphage in Ground Water
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
6. BCA Announces a New Member Joins Its Blood Center Coperative
7. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
8. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
9. Vivid Learning Systems Announces Newly Designed Industry Websites for MSHA, Electrical Utility Safety, Healthcare and OSHA Compliance
10. Nanounity Announces That the Delmic SECOM Correlative Microscopy System Has Won a 2013 Microscopy Today Innovation Award.
11. Natural Acne Remedy, Probiotic Action, Announces the Unveiling of their New Probiotic Acne Cleanser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):